ADELAIDE, Australia & SAN FRANCISCO — For decades, cardiologists and health professionals have routinely advised patients diagnosed with atrial fibrillation (AFib) to eliminate or severely restrict caffeinated coffee, fearing it could act as a direct trigger for irregular heart rhythms.
However, groundbreaking clinical trial data published in JAMA is challenging this long-held medical consensus, suggesting that moderate daily coffee consumption is not only safe for most AFib patients, but may actually significantly reduce the risk of arrhythmia recurrence following treatment.
The DECAF Clinical Trial: Challenging Decades of Medical Assumptions
Led by researchers from the University of Adelaide and the University of California, San Francisco (UCSF), the DECAF (Does Eliminating Coffee Avoid Fibrillation?) trial provided the first randomized, controlled evidence evaluating the direct impact of coffee on post-treatment heart rhythm stability.
The study evaluated 200 patients with a history of persistent atrial fibrillation or atrial flutter who had undergone cardioversion therapy to restore a normal heart rhythm. Following the procedure, participants were randomly assigned to either consume at least one cup of caffeinated coffee daily or abstain entirely from coffee and caffeinated products for six months.
-
39% Lower Risk of Recurrence: Patients in the daily coffee group demonstrated a 39% lower hazard rate of recurrent AFib or atrial flutter compared to those who completely abstained from caffeine.
-
47% vs 64% Recurrence Rates: Over the 6-month observation period, arrhythmia recurrence occurred in 47% of coffee drinkers compared to 64% of abstainers.
-
No Increase in Adverse Events: The study reported no significant differences in adverse medical events or hospitalizations between the coffee-consuming and abstaining groups.
DECAF Clinical Trial Findings Snapshot:
• Clinical Trial Name: DECAF (Does Eliminating Coffee Avoid Fibrillation?)
• Published Journal: JAMA (Journal of the American Medical Association)
• Trial Cohort: 200 AFib patients following cardioversion
• Key Outcome: 39% hazard reduction in AFib/flutter recurrence with daily coffee
• Dosage Evaluated: Approximately 1 cup of caffeinated coffee daily
Why Coffee May Protect Against Irregular Heart Rhythms
While caffeine has traditionally been viewed as a stimulant that could provoke heart palpitations, researchers point out that coffee contains hundreds of biologically active compounds with potential cardiovascular benefits.
Potential Biological Mechanisms Under Study
-
Adenosine Receptor Blockade: Caffeine blocks A1 and A2a adenosine receptors, potentially inhibiting adenosine-mediated signaling pathways known to induce AFib episodes.
-
Anti-Inflammatory & Antioxidant Properties: Coffee is a rich source of polyphenols and antioxidants, which may reduce systemic inflammation and cardiac tissue fibrosis.
-
Cardiometabolic & Lifestyle Factors: Moderate coffee intake has been linked to increased daily physical activity and subtle blood pressure regulation via mild diuretic effects, both of which support overall heart health.
What Doctors and AFib Patients Should Know Moving Forward
Lead investigators note that while the findings strongly argue against routine caffeine bans for heart rhythm patients, dietary choices should remain individualized.
Cardiologists suggest that patients with atrial fibrillation who already enjoy a daily cup of coffee or tea do not need to eliminate it unless they personally identify caffeine as a specific, repeatable trigger for their symptoms. Health experts caution, however, that these protective findings apply to naturally brewed coffee and tea—not high-dose synthetic energy drinks or excessive caffeine consumption.
Comment